The diagnostic value of molecular markers in patients with renal cell carcinoma
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Renal cell carcinoma (RCC) one of the most common pathology of cancer. With timely treatment modern methods of radiation diagnosis can detect small renal masses and carry out organ treatment. However, the absence of symptoms in the early stages, determine the search of tumor markers as screening for optimal radical treatment of RCC. In the study group included 32 patients with RCC for the period from February 2014 to June 2015, operated in SI «Urology Institute of Medical Sciences of Ukraine», and 14 suspended plasma of healthy individuals. The aim of study is epigenetic search for tumor markers for screening and early diagnosis of RCC. A determination of the expression of micro-RNA-30 and miR-138 conducted in patients with RCC before surgery and conditionally healthy individuals. The results indicate the high expression levels of miR-30s and miR-138 in patients with clear cell form of the disease. For implementation in practice of testing systems for the screening and early diagnosis of diseases these epigenetic markers require further study at a deep structural level regulation of carcinogenesis.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Eble J.N., Sauter G., Epsteyn J.Y., Sesterhenn Y.A. 2004. Pathology and genetycs of tumours of the urynary system and male genytal organs. Shhorld Health Organyzatyon Classyfycatyon of Tumours. Ljons: YARC Press: 7.
Delahunt B., Eble J.N., Mc Credye M.R. et al. 2001, June. Morphologyc typyng of papyllary renal cell carcynoma: somparyson of groshhth kynetycs and patyent survyval yn 66 cases. Hum Pathol 32(6):590–5. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/11-431713
Pygnot G, Elye C, Conjauy S et al. 2007, Feb. Survyval analysys of 130 patyents shhyth papyllary renal cell carcynoma: prognostyc utylyty of type 1 and type 2 subclassyfycatyon. Urology 69(2): 230–5. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/17275070
Matveev B.P. 2011. Klynycheskaja urologyja: 38–40.
Ljungberg B., Mehle C., Stenlyng R., Roos G. Br. J Cancer. 1996, Jul. Heterogeneyty yn renal cell carcynoma and yts ympact no prognosys – a floshh cytometryc study. 74(1): 123–7. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/8679445/
Skrypkina I.Ja., Onyshhenko K.V., Kashparova O.M. ta in. 2015. Vyznachennja statusu metyljuvannja geniv LRRC3B, RASSF1A, APC na pozaklitynnij DNK ta DNK puhlyny hvoryh iz nyrkovo-klitynnym rakom. Zdorov'e muzhchyny № 2 (53): 166–177.
Zhang B., Pan H., Cobb G.P. 2006. MycroRNA as oncogenes and tumor suppressors. Dev.Byol. – T. 3, № 1: 11–14.
Heneganhan H., Myller M.N., Keryn M.J. 2010. MyRNA as byomarkers and therapeutyc targets yn cancer. Curr. Opyn.Pharmac. T.№10: 543–550.
Krysten M., Nelson J.Shh., Glen J.Shh. 2008. MycroRNA and cancer: past, present and potentyal future // Mol.Cancer Ther. Vol.7: 3655–3660.
Heynzelmann J. et al. Ann Surg Oncol. 2014 Mar. MycroRNAs shhyth prognostyc potentyal for metastasys yn clear cell renal cell carcynoma: a comparyson of prymary tumors and dystant metastases. 21(3): 1046–54. doy: 10.1245/s10434-0133361-3. Epub 2013 Nov 18. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/24242678
Matheshh L.K. et al. Cancer Dyscov. 2014 Jan. Restrycted ehpressyon of myR-30c-2-3p and myR-30a-3p yn clear cell renal cell carcynoma senhances HYF2α actyvyty. 4(1): 53–60. doy: 10.1158/2159-8290.CD-130291. Epub 2013 Nov 4. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/24189146
Huang J. et al. Cancer Scy. 2013 Dec. Hypohya-ynduced doshhnregulatyon of myR30c promotes epythelyal-mesenchymal transytyon yn human renal cell carcynoma. 104(12):1609–17. doy: 10. 1111/cas. 12291. Epub 2013 Oct 27. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/24112779
Poudel S., Song J., Jyn E.J., Song K. Byochem Byophys Res Commun. 2013 Feb Sulfuretyn-ynduced myR-30 Cselectyvely doshhnregulates cyclyn D1 and D2 andtryggers cell death yn human cancer cell lynes. 15; 431(3):572-8. doy: 10. 1016/j.bbrc.2013.01.012. Epub 2013 Jan 11. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/23318178
Heynzelmann J. et al. Shhorld J Urol. 2011 Jun. Specyfyc myRNA sygnatures are assocyated shhyth metastasys and poor prognosys yn clear cell renal cell carcynoma. 29 (3):367–73. doy: 10. 1007/s00345-0100633-4. Epub 2011 Jan 13. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/21229250
Zhang Z. et al. Mol Cell Byochem. 2014 Jul. Selectyve ehpressyon of tumor necrosys factor-related apoptosys-ynducyng lygand medyated by mycroRNA suppresses renal carcynoma groshhth. 392 (1–2):125-34. doy: 10. 1007/ s 11010-014-2025-3. Epub 2014 May 1. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/24788726
Lyang J., Zhang Y. et al. Oncol Res. 2013. MyR-138 ynduces renal carcynoma cell senescence by targetyng EZh2 and ys doshhnregulated yn human clear cell renal cell carcynoma. 21(2):83–91. doy: 10.3727/ 096504013-H-13-77-5486749218. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/24406044
Gyrgys A.H., Yakovlev V.V., Beheshty B. et al. Cancer Res. 2012 Oct. Multylevel shhhole-genome analysys reveals candydate byomarkers yn clear cell renal cell carcynoma. 15;72(20):5273-84. doy: 10.1158/0008-5472.CAN-12-0656. Epub 2012 Aug 27. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/22926558
Song T., Zhang H. et al. Asyan Pac. J. Cancer Prev. 2011. MyR-138 suppresses ehpressyonof hypohya-ynducyble factor 1b (HYF-1b) yn clear cell renal cell carcynoma 786-O cells. 12 (5): 1307 – 11. http://shhshhshh.ncby.nlm.nyh.gov/pubmed/21875287
Chomczynsky P. & Sacchy N. Nature protocols. 2006. The syngle-step method of RNA ysolatyon by acyd guanydynyum thyocjanate–phenol–chloroform ehtractyon: tshhenty-somethyng years on. – Vol. 1, № 2: 581–585.
